The Lancet Oncology· Kaixiong Tao, Zhenyu Lin, Peng Zhang, Pan Chi, Yi Xiao, Zhiguo Hou, Ximing Xu, Aimin Zhang, Xingfeng Qiu, Junxin Wu, Ying Yuan, Zhenning Wang, Xiujuan Qu, Xin Li, Xiu Nie, Ming Yang, Kailin Cai, Zheng Wang, Weikang Zhang, Ying Huang, Zhen Sun, Rongrong Zheng, Feng Zhao, Chuyi Han, Tao Zhang·· 3 小时前精选评分63
UNION三期中期分析：短程放疗联合卡瑞利珠单抗和CAPOX显著改善局部晚期直肠癌三年无事件生存
[Articles] Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial
导读
UNION多中心开放标签三期试验预设中期分析显示，新辅助短程放疗联合卡瑞利珠单抗和CAPOX治疗局部晚期直肠癌，与标准长程放化疗联合CAPOX相比，显著改善三年无事件生存，安全性特征相似。研究者认为该新疗法前景值得与当代全新辅助治疗策略进一步比较。
推荐理由
三期临床中期分析显示短程放疗联合卡瑞利珠单抗和CAPOX显著改善三年无事件生存，安全性与标准长程放化疗相当。
来源：The Lancet Oncology · thelancet.com